Lyotropic Liquid Crystalline Phase Nanostructure and Cholesterol Enhance Lipid Nanoparticle Mediated mRNA Transfection in Macrophages
Source abstract
Abstract
Abstract Macrophages are unique immune cells attracting growing attention as a potential candidate for cell‐based therapy for infectious diseases and cancer. Strategies that can reprogramme or gene‐edit macrophages hold potential across a spectrum of acute and chronic conditions. Herein, lipid nanoparticles (LNPs) are developed containing the ionizable lipid SM‐102, helper lipid monoolein which is known for self‐assembly in aqueous solutions into the inverse cubic lyotropic liquid crystalline mesophase, and cholesterol as an mRNA nanocarrier. The immortalized alveolar macrophage cell line (MH‐S cells) is utilized to investigate how cholesterol concentration impacts on mRNA delivery which is further validated using primary mouse alveolar macrophages isolated from the bronchoalveolar compartment and human monocyte derived macrophages. By using high‐throughput synchrotron small angle X‐ray scattering (SAXS), an acidification‐induced non‐ordered to ordered internal nanostructure transition of the formulated LNPs is observed, following the transition sequence of inverse micellar to hexagonal to cubic mesophase in the pH range from 7 to 4. Cholesterol is identified as another crucial component for superior mRNA transfection in macrophages, contributing to nanostructure transition and protein corona variation. Successful ex vivo mRNA transfection is also achieved in primary macrophages, highlighting the prospectivity of reprogramming macrophages as a cell therapy for lung diseases.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Surfactants and Colloidal Systems · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Centre for Respiratory Science & Health School of Health & Biomedical Sciences RMIT University Bundoora VIC 3083 Australia
School of Science STEM College RMIT University Melbourne VIC 3000 Australia
UniSA Clinical and Health Sciences University of South Australia Adelaide SA 5000 Australia
CSIRO Manufacturing Bayview Avenue Clayton VIC 3169 Australia
Funding
Australian Research Council · Australian Institute of Nuclear Science and Engineering
References (66)
Show source-provided references
1. W. H. Organization The top 10 causes of death https://www.who.int/news‐room/fact‐sheets/detail/the‐top‐10‐causes‐of‐death(accessed: March 2024).
2. 10.1016/S0140-6736(21)00458-X10.1016/S0140-6736(21)00458-X ↗
3. 10.1016/S2213-2600(20)30105-310.1016/S2213-2600(20)30105-3 ↗
4. 10.1016/S0140-6736(12)61728-010.1016/S0140-6736(12)61728-0 ↗
5. 10.3322/caac.2166010.3322/caac.21660 ↗
6. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
7. 10.1021/acsnanoscienceau.2c0006210.1021/acsnanoscienceau.2c00062 ↗
8. 10.1016/j.fmre.2023.02.02210.1016/j.fmre.2023.02.022 ↗
9. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
10. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
11. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
12. 10.1016/j.ejps.2023.10637010.1016/j.ejps.2023.106370 ↗
13. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
14. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
15. 10.1016/j.immuni.2022.08.01010.1016/j.immuni.2022.08.010 ↗
16. 10.1164/arrd.1978.118.4.79110.1164/arrd.1978.118.4.791 ↗
17. 10.1067/mai.2001.11284510.1067/mai.2001.112845 ↗
18. 10.1038/s12276-023-01068-z10.1038/s12276-023-01068-z ↗
19. 10.1038/s41573-022-00520-510.1038/s41573-022-00520-5 ↗
20. 10.1097/HS9.000000000000068210.1097/HS9.0000000000000682 ↗
21. 10.1038/s41467-019-11911-510.1038/s41467-019-11911-5 ↗
22. Yu H. · J. Am. Chem. Soc. · 2023 · 145
23. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
24. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
25. 10.1016/j.actbio.2021.06.02310.1016/j.actbio.2021.06.023 ↗
26. 10.1039/C9NR09347H10.1039/C9NR09347H ↗
27. 10.1016/j.bbamem.2012.05.01710.1016/j.bbamem.2012.05.017 ↗
28. 10.1073/pnas.172054211510.1073/pnas.1720542115 ↗
29. 10.1016/j.xphs.2022.12.02610.1016/j.xphs.2022.12.026 ↗
30. 10.1038/s41467-019-12508-810.1038/s41467-019-12508-8 ↗
31. Van Hoecke L. · J. Vis. Exp. · 2017 · 123
32. 10.1002/anie.20230497710.1002/anie.202304977 ↗
33. 10.1016/j.ijpharm.2011.01.02210.1016/j.ijpharm.2011.01.022 ↗
34. 10.1039/C0CP01539C10.1039/C0CP01539C ↗
35. 10.1039/f2976720152510.1039/f29767201525 ↗
36. 10.1021/acsnano.3c0109510.1021/acsnano.3c01095 ↗
37. 10.1021/jz400857z10.1021/jz400857z ↗
38. 10.1021/acsnano.5b0390210.1021/acsnano.5b03902 ↗
39. 10.1002/advs.20180122310.1002/advs.201801223 ↗
40. 10.1021/acs.langmuir.2c0149210.1021/acs.langmuir.2c01492 ↗
41. 10.1021/acsnano.8b0151610.1021/acsnano.8b01516 ↗
42. 10.1021/ar300285u10.1021/ar300285u ↗
43. 10.1016/S0006-3495(02)75339-310.1016/S0006-3495(02)75339-3 ↗
44. 10.1016/0304-4157(90)90002-T10.1016/0304-4157(90)90002-T ↗
45. 10.1038/s41467-024-45666-510.1038/s41467-024-45666-5 ↗
46. 10.1021/acsnano.0c1006410.1021/acsnano.0c10064 ↗
47. 10.1016/j.jcis.2023.12.16510.1016/j.jcis.2023.12.165 ↗
48. 10.1038/s41467-022-33157-410.1038/s41467-022-33157-4 ↗
49. 10.1021/mp200374e10.1021/mp200374e ↗
50. 10.1038/s41467-020-14527-210.1038/s41467-020-14527-2 ↗
51. 10.1128/JVI.00422-0810.1128/JVI.00422-08 ↗
52. 10.1073/pnas.061145010410.1073/pnas.0611450104 ↗
53. 10.1021/bi00381a00510.1021/bi00381a005 ↗
54. 10.1016/j.jcis.2023.11.05910.1016/j.jcis.2023.11.059 ↗
55. 10.1016/S0378-5173(00)00531-710.1016/S0378-5173(00)00531-7 ↗
56. 10.1021/ja208433810.1021/ja2084338 ↗
57. 10.1016/j.jcis.2023.03.04810.1016/j.jcis.2023.03.048 ↗
58. 10.15252/embj.202110865010.15252/embj.2021108650 ↗
59. 10.1021/nn406018q10.1021/nn406018q ↗
60. 10.1021/acs.langmuir.5b0215810.1021/acs.langmuir.5b02158 ↗
61. 10.1161/ATVBAHA.112.30038310.1161/ATVBAHA.112.300383 ↗
62. 10.1021/acsnano.2c1079010.1021/acsnano.2c10790 ↗
63. 10.1021/jacs.0c0185310.1021/jacs.0c01853 ↗
64. 10.1038/s41419-022-04589-z10.1038/s41419-022-04589-z ↗
65. 10.1074/mcp.TIR119.00161610.1074/mcp.TIR119.001616 ↗
66. 10.1385/1-59259-890-0:57110.1385/1-59259-890-0:571 ↗